Quality, Value, Momentum Scores
This card shows the Quality, Value, and Momentum scores for the company
Income Statement: Revenue, Operating Income, Net Income
- The operating income for Kalaris Therapeutics, Inc. as of June 30, 2025 is -67.59 MM.
- The net income for Kalaris Therapeutics, Inc. as of June 30, 2025 is -81.66 MM.
| Period End (TTM) | Revenue (MM) | Operating Income (MM) | Net Income (MM) |
| 2025-06-30 | -67.59 | -81.66 | |
| 2025-03-31 | -59.52 | -75.96 | |
| 2024-12-31 | -51.73 | -69.17 | |
| 2024-09-30 | -48.06 | -50.61 | |
| 2023-12-31 | -13.46 | -14.70 | |
| 2022-12-31 | -14.01 | -15.48 |
Income Statement: EPS
| Period End (TTM) | Earnings Per Share Basic | Earnings Per Share Diluted |
| 2025-06-30 | ||
| 2025-03-31 | -10.39 | -10.39 |
| 2024-12-31 | -10.44 | |
| 2024-09-30 | -7.71 | -7.71 |
| 2023-12-31 | -2.42 | |
| 2022-12-31 | -3.48 |
Cash Flow: Operations, Investing, Financing
- The cash from operating activities for Kalaris Therapeutics, Inc. as of June 30, 2025 is -32.16 MM.
- The cash from financing activities for Kalaris Therapeutics, Inc. as of June 30, 2025 is 114.84 MM.
| Period End (TTM) | Cash From Operating Activities (MM) | Cash From Investing Activities (MM) | Cash From Financing Activities (MM) |
| 2025-06-30 | -32.16 | 114.84 | |
| 2025-03-31 | -23.59 | 119.83 | |
| 2024-12-31 | -20.67 | 19.14 | |
| 2024-09-30 | -16.95 | 18.42 | |
| 2023-12-31 | -14.13 | 14.24 | |
| 2022-12-31 | -9.78 | 12.78 |
Valuation Metrics : PE, PriceToBook, PriceToTBV
- The p/book for Kalaris Therapeutics, Inc. as of June 30, 2025 is 0.78.
- The p/tbv for Kalaris Therapeutics, Inc. as of June 30, 2025 is 0.78.
- P/Book
- The current closing price divided by the book value per share.
- P/TBV
- The current price divided by the tangible book value per share.
| Period End (TTM) | p/e | P/Book | P/TBV |
| 2025-06-30 | 0.78 | 0.78 | |
| 2025-03-31 | -2.33 | -3.18 | -3.18 |
| 2024-12-31 | -0.25 | -0.35 | -0.18 |
| 2024-09-30 | -0.35 | -0.41 | -0.20 |
| 2023-12-31 | |||
| 2022-12-31 |
Valuation Metrics : EBitToEv, EBit3YrAvgToEv
- The ebit/ev for Kalaris Therapeutics, Inc. as of June 30, 2025 is -5.20.
- The ebit (3y)/ev for Kalaris Therapeutics, Inc. as of June 30, 2025 is -2.42.
| Period End (TTM) | EBIT/EV | EBIT (3y)/EV |
| 2025-06-30 | -5.20 | -2.42 |
| 2025-03-31 | -0.31 | -0.15 |
| 2024-12-31 | -0.84 | -0.40 |
| 2024-09-30 | -0.71 | -0.31 |
| 2023-12-31 | 0.00 | 0.00 |
| 2022-12-31 |
Management Effectiveness
- The roa for Kalaris Therapeutics, Inc. as of June 30, 2025 is -22.79.
- The roic for Kalaris Therapeutics, Inc. as of June 30, 2025 is -0.91.
- The croic for Kalaris Therapeutics, Inc. as of June 30, 2025 is 1.15.
- The ocroic for Kalaris Therapeutics, Inc. as of June 30, 2025 is -0.28.
| Period End (TTM) | ROA | ROE | ROIC | CROIC | OCROIC |
| 2025-06-30 | -22.79 | -0.91 | 1.15 | -0.28 | |
| 2025-03-31 | -20.75 | ||||
| 2024-12-31 | -20.75 | ||||
| 2024-09-30 | |||||
| 2023-12-31 | |||||
| 2022-12-31 |
Gross Margins
- Gross Margin
- The Gross Margin is the ratio of revenue left after substracting the Cost of Goods Sold. It is calculated as 1.0 - (Revenue - COGS ) / Revenue.
- Net Margin
- The Net Margin (aka Profit Margin) is the ratio of revenue left after substracting the Net Income. It is calculated as Net Income / Revenue.
- Operating Margin
- The Operaing Margin is the ratio of revenue left after substracting the Operating Income. It is calculated as Operating Income / Revenue.
| Period End (TTM) | Gross Margin | Net Margin | Operating Margin |
| 2025-06-30 | |||
| 2025-03-31 | |||
| 2024-12-31 | |||
| 2024-09-30 | |||
| 2023-12-31 | |||
| 2022-12-31 |
Identifiers and Descriptors
| Central Index Key (CIK) |
